AAAAAA

   
Results: 1-10 |
Results: 10
EFFICACY OF INTRAHEPATIC CHEMOTHERAPY FOR LIVER METASTASES OF RARE GASTROINTESTINAL-TRACT AND OTHER RARE CANCERS
Authors: LEDER GH LINK KH FORMENTINI A WIDMAIER U PILLASCH J BEGER HG
Citation: Gh. Leder et al., EFFICACY OF INTRAHEPATIC CHEMOTHERAPY FOR LIVER METASTASES OF RARE GASTROINTESTINAL-TRACT AND OTHER RARE CANCERS, European journal of cancer, 33, 1997, pp. 1278-1278
PALLIATIVE AND ADJUVANT REGIONAL CHEMOTHERAPY IN PANCREATIC-CANCER
Authors: LINK KH GANSAUGE F GORICH J LEDER GH RILINGER N BEGER HG
Citation: Kh. Link et al., PALLIATIVE AND ADJUVANT REGIONAL CHEMOTHERAPY IN PANCREATIC-CANCER, European journal of surgical oncology, 23(5), 1997, pp. 409-414
THYMIDYLATE SYNTHASE IS A PREDICTOR FOR RESPONSE AND RESISTANCE IN HEPATIC-ARTERY INFUSION CHEMOTHERAPY
Authors: KORNMANN M LINK KH LENZ HJ PILLASCH J METZGER R BUTZER U LEDER GH WEINDEL M SAFI F DANENBERG KD BEGER HG DANENBERG PV
Citation: M. Kornmann et al., THYMIDYLATE SYNTHASE IS A PREDICTOR FOR RESPONSE AND RESISTANCE IN HEPATIC-ARTERY INFUSION CHEMOTHERAPY, Cancer letters, 118(1), 1997, pp. 29-35
REGIONAL CHEMOTHERAPY DIRECTED BY INDIVIDUAL CHEMOSENSITIVITY TESTINGIA VITRO - A PROSPECTIVE DECISION-AIDING TRIAL
Authors: LINK KH KORNMANN M LEDER GH BUTZER U PILLASCH J STAIB L GANSAUGE F BEGER HG
Citation: Kh. Link et al., REGIONAL CHEMOTHERAPY DIRECTED BY INDIVIDUAL CHEMOSENSITIVITY TESTINGIA VITRO - A PROSPECTIVE DECISION-AIDING TRIAL, Clinical cancer research, 2(9), 1996, pp. 1469-1474
NO SUPPORTS TUMOR-GROWTH BY SUPPRESSION O F LYMPHOCYTES - EXPERIMENTSIN-VIVO
Authors: LEDER GH OPPENHEIM M ROSENSTEIN M HOFFMAN R LOTZE MT BEGER HG
Citation: Gh. Leder et al., NO SUPPORTS TUMOR-GROWTH BY SUPPRESSION O F LYMPHOCYTES - EXPERIMENTSIN-VIVO, Langenbecks Archiv fur Chirurgie, 1996, pp. 181-184
INHIBITION OF NITRIC-OXIDE SYNTHESIS DOES NOT IMPROVE INTERLEUKIN-2-MEDIATED ANTITUMOR EFFECTS IN-VIVO
Authors: LEDER GH OPPENHEIM M ROSENSTEIN M SHAH N HOFFMAN R LOTZE MT BEGER HG
Citation: Gh. Leder et al., INHIBITION OF NITRIC-OXIDE SYNTHESIS DOES NOT IMPROVE INTERLEUKIN-2-MEDIATED ANTITUMOR EFFECTS IN-VIVO, European surgical research, 28(3), 1996, pp. 167-178
ADDITION OF INTERLEUKIN-12 TO LOW-DOSE INTERLEUKIN-2 TREATMENT IMPROVES ANTITUMOR EFFICACY IN-VIVO
Authors: LEDER GH OPPENHEIM M ROSENSTEIN M LOTZE MT BERGER HG
Citation: Gh. Leder et al., ADDITION OF INTERLEUKIN-12 TO LOW-DOSE INTERLEUKIN-2 TREATMENT IMPROVES ANTITUMOR EFFICACY IN-VIVO, Zeitschrift fur Gastroenterologie, 33(9), 1995, pp. 499-502
FLOW-CYTOMETRIC DETERMINATION OF PEPTIDE CLASS-I COMPLEX-FORMATION - IDENTIFICATION OF P53 PEPTIDES THAT BIND TO HLA-A2
Authors: ZEH HJ LEDER GH LOTZE MT SALTER RD TECTOR M STUBER G MODROW S STORKUS WJ
Citation: Hj. Zeh et al., FLOW-CYTOMETRIC DETERMINATION OF PEPTIDE CLASS-I COMPLEX-FORMATION - IDENTIFICATION OF P53 PEPTIDES THAT BIND TO HLA-A2, Human immunology, 39(2), 1994, pp. 79-86
IDENTIFICATION OF WILD-TYPE AND MUTANT P53 PEPTIDES BINDING TO HLA-A2ASSESSED BY A PEPTIDE LOADING-DEFICIENT CELL-LINE ASSAY AND A NOVEL MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I PEPTIDE BINDING ASSAY
Authors: STUBER G LEDER GH STORKUS WJ LOTZE MT MODROW S SZEKELY L WOLF H KLEIN E KARRE K KLEIN G
Citation: G. Stuber et al., IDENTIFICATION OF WILD-TYPE AND MUTANT P53 PEPTIDES BINDING TO HLA-A2ASSESSED BY A PEPTIDE LOADING-DEFICIENT CELL-LINE ASSAY AND A NOVEL MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I PEPTIDE BINDING ASSAY, European Journal of Immunology, 24(3), 1994, pp. 765-768
MUTATIONAL INACTIVATION OF THE P53 GENE IN THE HUMAN ERYTHROID LEUKEMIC K562 CELL-LINE
Authors: LAW JC RITKE MK YALOWICH JC LEDER GH FERRELL RE
Citation: Jc. Law et al., MUTATIONAL INACTIVATION OF THE P53 GENE IN THE HUMAN ERYTHROID LEUKEMIC K562 CELL-LINE, Leukemia research, 17(12), 1993, pp. 1045-1050
Risultati: 1-10 |